Add to Favorites

China Lung Cancer Diagnosis Market 2013-2023: Unmet Needs & Opportunities




Report Overview

According to the Chinese Cancer Registry Annual Report 2012, lung cancer has the highest incidence among all types of cancer in China and it is also the No.1 killer among the urban population. The registered lung cancer mortality rate has increased by an astonishing 460% over the past three decades. This has imposed enormous burden on patients, health-care professionals and the society alike. Given China’s large population and its high incidence rate of lung cancer, the market of lung cancer diagnosis has great potential opportunities in future.


Through Loudon’s research effort, this report will put you in the right path of strategic thinking and serve to provide some answers to the frequently asked questions: What is the current market landscape of lung cancer diagnosis, the opportunities and challenges and segments of lung cancer diagnostic markets, including imaging tests, tumor markers, immunohistochemical test and histopathologic examinations.



Key Report Features

  • Summary of Key Findings

  • Patient Flow Analysis Lung Cancer Diagnosis
          - Screening and confirmation Places
          - Diagnosis of patients screened in PEC (physical examination centers)
          - Diagnosis of patients screened in hospital departments

  • Value Chain Analysis Lung Cancer Diagnosis

  • Staging of Lung Cancer

  • Evaluation on diagnosis tools
          - Evaluation on diagnosis tools
          - Hospital service prices lung cancer examination items
          - Unmet needs analysis

  • Market Overview and Projection 2013-2023
          - Lung cancer incident population
          - Market imaging tests and tumor marker
          - Market immunohistochemical test, endoscopy & biopsy
          - Lung cancer diagnosis market by product segments
          - Lung cancer diagnosis market by rural and urban population

The report is in about 44 pages in English presentation format.


Who Would Benefit From This Report?

CEOs
Sales & Marketing VPs
R & D
BD/Marketing/ Medical Directors
Researchers
Financial Analysts in pharmaceutical, medical device
Private and institutional investors in life science industry
Payer organizations / Insurance companies
Organizations/ Authorities that concerns anti-smoking

Publication date

Aug 15, 2013.


Cost

5,000 RMB or 800 USD per subscription.



*You can send E-mailEmail to LFE to purchase this report.


Please transfer the RMB or USD payments to the following account:

 

A/C: Shanghai Loudon Marketing Consultant Co., Ltd
A/C: No. 444259223258
Bank Name: Bank of China Shanghai, FanYu Road Sub-branch
Swift code: BKCHCNBJ300

 

Name Beneficiary：Loudon Far East B.V. The Netherlands
Bank Name：ING Bank N.V.
Account No：67.38.48.906
IBAN：NL23INGB 0673848906
BIC/SWIFT：INGBNL2A

 

 

 



Ordering application form

Step 1:

Please choose the report you are interested in, click "More information" button.

Step 2:

Please go through the brief introduction of the report carefully and click "E-mail" link in the end of the page.

Step 3:

Please finish filling your required information in the e-mail.

Step 4:

After sending E-mail to Loudon, our client service person will contact you afterwards.


*If any questions, please contact our client service person.

Tel: +86-21-6290 2121-107

Email: jenny.zhu@loudon-research.com

(All free during 10:00~18:00 every work-day)